This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Boston Scientific Reports Lotus™ Valve System Met Primary Performance Endpoint In REPRISE II Trial

PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of the Lotus™ Valve System in symptomatic patients with severe aortic valve disease considered at high risk for surgical valve replacement.  The Lotus Valve System is the first transcatheter aortic valve replacement (TAVR) device of its kind with an Adaptive Seal™ that is designed to minimize aortic regurgitation (leaking), a proven predictor of mortality, and is both fully repositionable and retrievable prior to release.  Data were presented today as a late-breaking clinical trial at the EuroPCR Scientific Program in Paris by Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia, and principal investigator of the REPRISE II trial.  The data demonstrated that the Lotus Valve System met the primary performance endpoint for the first 60-patient cohort and was implanted successfully in all patients (60/60 patients) with no case of severe paravalvular regurgitation.

REPRISE II is an ongoing prospective, single-arm study that has completed enrollment of 120 patients at fourteen sites in Australia, France, Germany and the United Kingdom.  All patients had severe symptomatic aortic stenosis and were considered at high risk for surgical valve replacement.  REPRISE II is being extended to enroll an additional 130 patients at twenty sites in Australia and Europe.

  • The primary device performance endpoint was met as the 30-day mean aortic valve pressure gradient of 11.28 +5.23 mmHg with a one-sided upper confidence bound of 13.09 was significantly less (P<0.0001) than the performance goal of 18 mmHg.
  • The primary safety endpoint, defined as all-cause mortality at 30 days, was 1.7 percent.
  • Independent core lab assessment of paravalvular aortic regurgitation at 30 days indicated no severe regurgitation and one case of moderate regurgitation (1.9 percent).  In 79.2 percent of patients there was trace or no paravalvular regurgitation at 30 days.
  • No instances of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.

"The ability to initially position the Lotus valve very precisely and, if needed, to easily reposition or indeed fully retrieve the valve provide the operator with remarkable control," said Professor Meredith.  "When combined with immediate and near complete elimination of aortic regurgitation, even in patients who began with moderate or severe aortic regurgitation, the results are impressive and reflect very favorably on the unique features of the Lotus technology."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs